PTC Therapeutics Inc.

06/05/2026 | Press release | Distributed by Public on 06/05/2026 15:15

Proxy Results (Form 8-K)

Item 5.07. Submission of Matters to a Vote of Security Holders.

The Company held its Annual Meeting on June 2, 2026 (the "Annual Meeting"). The results for the votes regarding each proposal at the Annual Meeting are set forth below. As of the record date of the Annual Meeting, April 10, 2026, there were 82,911,783 shares of the Company's common stock outstanding. Each share of common stock entitled its holder to one vote per share.

The stockholders of the Company elected four Class I directors, each to hold office until the Company's 2029 annual meeting of stockholders or until his or her successor has been duly elected and qualified, as follows:

Director

For

Withheld

Broker Non-Votes

Jessica Chutter

71,945,515

737,780

3,858,311

Matthew B. Klein, M.D., M.S., F.A.C.S.

71,550,878

1,132,417

3,858,311

Stephanie S. Okey, M.S.

68,902,707

3,780,588

3,858,311

Jerome B. Zeldis, M.D., Ph.D.

69,821,943

2,861,352

3,858,311

The appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 was ratified by the Company's stockholders with 76,170,292 votes "For," 355,794 votes "Against," and 15,520 votes "Abstained."

The non-binding advisory proposal on named executive officer compensation was approved by the Company's stockholders with 71,166,204 votes "For," 1,492,801 votes "Against," 24,290 votes "Abstained," and 3,858,311 broker non-votes.

PTC Therapeutics Inc. published this content on June 05, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT) on June 05, 2026 at 21:15 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]